PureTech Announces Presentation of New Data Supporting Wholly Owned Immuno-Oncology Programs LYT-200 (anti-galectin-9) & LYT-...
05 Noviembre 2019 - 7:00AM
Business Wire
Findings further validate targeting galectin-9
as therapeutic approach and biomarker for a number of
difficult-to-treat cancers
Preclinical data show potency of LYT-210
against pathogenic γδ1 T cells, major sources of immunosuppression
and resistance to immunotherapy in cancer
Posters Presented at Society for Immunotherapy
of Cancer (SITC) 34th Annual Meeting
PureTech Health plc (LSE: PRTC) (“PureTech”), a clinical-stage
biotechnology company dedicated to discovering, developing and
commercializing highly differentiated medicines for devastating
diseases, today announced the presentation of new preclinical data
from its wholly-owned immuno-oncology programs at the Society for
Immunotherapy of Cancer (SITC) 34th Annual Meeting in National
Harbor, Md.
The two scientific posters detail the Company’s continued
progress in advancing two fully human monoclonal antibodies (mAbs)
developed to inhibit two foundational immunosuppressive
orchestrators, galectin-9 (LYT-200) and pathogenic gamma delta-1
(γδ1) T cells (LYT-210).
“These data further show the unique position and importance of
galectin-9 and γδ1 as immunosuppressors in cancer biology. Both
have been observed to have powerful properties to disable
immune-mediated cancer attack, which may explain some of the
fundamental efficacy limitations of other immuno-oncology
therapies,” said Joseph Bolen, PhD, chief scientific officer at
PureTech. “Our novel antibodies targeting galectin-9 and γδ1 have
produced compelling single-agent preclinical data against a number
of difficult-to-treat cancers in models where approved
immunotherapies haven’t worked. We are excited to share our
continued progress with the scientific community at premier
conferences such as SITC.”
The new data presented at SITC indicate that galectin-9 is not
only a potent therapeutic target, but also a potentially relevant
biomarker. Across multiple cohorts, galectin-9 was significantly
increased in blood samples of individuals with primary and
metastatic pancreatic cancer, lung tumors, and colorectal
carcinoma, compared to healthy individuals.
“These findings validate the importance of galectin-9 in cancer
biology and its potency as a target,” said George Miller, MD,
Director of S. Arthur Localio Laboratories and Director of the
Cancer Immunology Program at NYU School of Medicine and a PureTech
collaborator. “Our research indicates that galectin-9 is a master
immunosuppressor; it induces a highly favorable microenvironment
for tumor growth. LYT-200 has potential both as a single agent and
in combination with checkpoint inhibitors to have therapeutic
potential by reversing the immunosuppression which can be present
in the tumor microenvironment.”
PureTech expects to file an Investigational New Drug application
(IND) for LYT-200 in the first half of 2020 and to initiate a Phase
1a/1b clinical trial in solid tumors in 2020. The mAb has been
tested as a single agent as well as in combination with anti-PD1
checkpoint inhibitors in preclinical murine and human-derived ex
vivo models, showing robust and reproducible activity, immune
activation potential as well as excellent drug properties.
PureTech also presented data on its monoclonal antibody LYT-210
that targets γδ1 T cells whose immunosuppressive features leads to
a tumor permissive microenvironment. The research presented at SITC
showed that γδ1 T cells were the most abundant T cell within the
studied tumors, which included pancreatic, colorectal,
cholangiocarcinoma, and liver cancer, and represented up to 50% of
all infiltrating T cells. PureTech also presented data showing that
LYT-210 depletes immunosuppressive γδ1 T cells through cytotoxicity
and phagocytosis. Together, these findings further support the
ability of LYT-210 to potentially restore the immune system’s
ability to fight difficult-to-treat cancers. PureTech expects to
file an IND for LYT-210 in 2021 for solid tumors.
“These data show that γδ1 cells play a key role in suppressing
the immune system’s ability to attack tumors. LYT-210 is designed
to remove and destroy pathogenic γδ1 T cells enabling immune
mediated cancer attack. We therefore believe LYT-210 holds
significant promise as a potential immunotherapy,” said Dr.
Miller.
About PureTech
PureTech is a clinical stage biotechnology company dedicated to
discovering, developing and commercializing highly differentiated
medicines for devastating diseases, including intractable cancers,
lymphatic and gastrointestinal diseases, central nervous system
disorders, and inflammatory and immunological diseases, among
others. The Company has created a broad and deep pipeline through
the expertise of its experienced research and development team and
its extensive network of scientists, clinicians and industry
leaders. This pipeline, which is being advanced both internally and
through PureTech’s affiliates, is comprised of 24 product
candidates and one product that has been cleared by the US Food and
Drug Administration (FDA). All of the underlying programs and
platforms that resulted in this pipeline of product candidates were
initially identified or discovered and then advanced by the
PureTech team through key validation points based on the Company’s
unique insights into the biology of the brain, immune, and gut, or
BIG, systems and the interface between those systems, referred to
as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191105005190/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com
US media Tom Donovan +1 857 559 3397
tom@tenbridgecommunications.com
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De May 2023 a May 2024